{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:56:00Z","timestamp":1775588160480,"version":"3.50.1"},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,14]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To date, there has been little agreement on what drug is the \"best\" drug for treating severe COVID-19 patients. This study aimed to assess the efficacy and safety of different medications available at present for severe COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched databases for randomized controlled trials (RCTs) published up to February 28, 2022, with no language restrictions, of medications recommended for patients (aged 16 years or older) with severe COVID-19 infection. We extracted data on trials and patient characteristics, and the following primary outcomes: all-cause mortality (ACM), and treatment-emergent adverse events (TEAEs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We identified 4021 abstracts and of these included 48 RCTs comprising 9147 participants through database searches and other sources. For decrease in ACM, we found that ivermectin\/doxycycline, C-IVIG (i.e., a hyperimmune anti-COVID-19 intravenous immunoglobulin), methylprednisolone, interferon-beta\/standard-of-care (SOC), interferon-beta-1b, convalescent plasma, remdesivir, lopinavir\/ritonavir, immunoglobulin gamma, high dosage sarilumab (HS), auxora, and imatinib were effective when compared with placebo or SOC group. We found that colchicine and interferon-beta\/SOC were only associated with the TEAEs of severe COVID-19 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study suggested that ivermectin\/doxycycline, C-IVIG, methylprednisolone, interferon-beta\/SOC, interferon-beta-1b, convalescent plasma (CP), remdesivir, lopinavir\/ritonavir, immunoglobulin gamma, HS, auxora, and imatinib were efficacious for treating severe COVID-19 patients. We found that most medications were safe in treating severe COVID-19. More large-scale RCTs are still needed to confirm the results of this study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030998","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T23:09:50Z","timestamp":1665788990000},"page":"e30998","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-911X","authenticated-orcid":false,"given":"Qinglin","family":"Cheng","sequence":"first","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou, China"},{"name":"School of Medicine, Hangzhou Normal University, Hangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Chen","sequence":"additional","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjun","family":"Jia","sequence":"additional","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Fang","sequence":"additional","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"n2239","DOI":"10.1136\/bmj.n2239","article-title":"Under-reporting of deaths limits our understanding of true burden of covid-19.","volume":"375","author":"Whittaker","year":"2021","journal-title":"BMJ"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results.","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e22948","DOI":"10.1002\/jbt.22948","article-title":"Antiviral drugs suppress infection of 2019-nCoV spike pseudotyped virus by interacting with ACE2 protein.","volume":"36","author":"Wang","year":"2022","journal-title":"J Biochem Mol Toxicol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.3346\/jkms.2021.36.e298","article-title":"Antivirals for coexistence with COVID-19: brief review for general physicians.","volume":"36","author":"Yoo","year":"2021","journal-title":"J Korean Med Sci"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis.","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e1003501e1003501","DOI":"10.1371\/journal.pmed.1003501","article-title":"Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis.","volume":"17","author":"Kim","year":"2020","journal-title":"PLoS Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12985-020-01412-z","article-title":"Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.","volume":"17","author":"Shrestha","year":"2020","journal-title":"Virol J"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"101058","DOI":"10.1016\/j.disamonth.2020.101058","article-title":"COVID-19: therapeutics and interventions currently under consideration.","volume":"66","author":"McFee","year":"2020","journal-title":"Dis Mon"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.","volume":"9","author":"Aman","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"5 Suppl 4","key":"R13-20250504","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1097\/TA.0b013e31827013e9","article-title":"he Eastern Association of the Surgery of Trauma approach to practice management guideline development using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.","volume":"73","author":"Kerwin","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"21866","DOI":"10.18632\/aging.203522","article-title":"Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.","volume":"13","author":"Cheng","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses.","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians.","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11606-021-07203-8","article-title":"Colchicine is safe though ineffective in the treatment of severe COVID-19: a randomized clinical trial (COLCHIVID).","volume":"37","author":"Absal\u00f3n-Aguilar","year":"2022","journal-title":"J Gen Intern Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"100926","DOI":"10.1016\/j.eclinm.2021.100926","article-title":"Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: a phase I\/II randomized control trial.","volume":"36","author":"Ali","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1038\/s41598-021-89444-5","article-title":"Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.","volume":"11","author":"AlQahtani","year":"2021","journal-title":"Sci Rep"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/sjmms.sjmms_731_20","article-title":"Safety and efficacy of convalescent plasma for severe COVID-19: interim report of a multicenter phase II Study from Saudi Arabia.","volume":"9","author":"AlShehry","year":"2021","journal-title":"Saudi J Med Med Sci"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e152740","DOI":"10.1172\/JCI152740","article-title":"A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.","volume":"131","author":"Avenda\u00f1o-Sol\u00e1","year":"2021","journal-title":"J Clin Invest"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/idr14020020","article-title":"Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial.","volume":"14","author":"Beltran-Gonzalez","year":"2022","journal-title":"Infect Dis Rep"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13054-022-03964-8","article-title":"Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial.","volume":"26","author":"Bruen","year":"2022","journal-title":"Crit Care"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19.","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial.","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized With severe COVID-19: a randomized clinical trial.","volume":"326","author":"Caricchio","year":"2021","journal-title":"JAMA"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2665-9913(21)00070-9","article-title":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.","volume":"3","author":"Cremer","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"e01061","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon \u03b2-1a in treatment of severe COVID-19.","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1093\/cid\/ciaa1443","article-title":"Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by coronavirus disease 2019 (COVID-19).","volume":"72","author":"de Alencar","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial.","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"2002808","DOI":"10.1183\/13993003.02808-2020","article-title":"Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.","volume":"56","author":"Edalatifard","year":"2020","journal-title":"Eur Respir J"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12879-020-05507-4","article-title":"The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.","volume":"20","author":"Gharebaghi","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.22578\/IJMS.19.1.14","article-title":"Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq.","volume":"19","author":"Hashim","year":"2021","journal-title":"Iraqi JMS"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"e0257238","DOI":"10.1371\/journal.pone.0257238","article-title":"Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: a randomized controlled trial.","volume":"16","author":"Hernandez-Cardenas","year":"2021","journal-title":"PLoS One"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial.","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults.","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s13054-020-03220-x","article-title":"Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial.","volume":"24","author":"Miller","year":"2020","journal-title":"Crit Care"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/aas.13941","article-title":"Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial.","volume":"65","author":"Munch","year":"2021","journal-title":"Acta Anaesthesiol Scand"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"e4166","DOI":"10.1093\/cid\/ciaa1041","article-title":"Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care.","volume":"73","author":"Olender","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R46-20250504","first-page":"1","article-title":"A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR).","volume":"3","author":"Patel","year":"2021","journal-title":"medRxiv"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"106903","DOI":"10.1016\/j.intimp.2020.106903","article-title":"Interferon \u03b2-1b in treatment of severe COVID-19: a randomized clinical trial.","volume":"88","author":"Rahmani","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"R48-20250504","first-page":"357","article-title":"The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.","volume":"28","author":"Rasheed","year":"2020","journal-title":"Infez Med"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1038\/s41598-021-88509-9","article-title":"An open-label randomized controlled trial evaluating the efficacy of chloroquine\/hydroxychloroquine in severe COVID-19 patients.","volume":"11","author":"R\u00e9a-Neto","year":"2021","journal-title":"Sci Rep"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia.","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"00059","DOI":"10.1183\/23120541.00059-2021","article-title":"A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1.","volume":"7","author":"Sehgal","year":"2021","journal-title":"ERJ Open Res"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","article-title":"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.","volume":"6","author":"Shi","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in Covid-19 severe pneumonia.","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"R54-20250504","first-page":"1","article-title":"A randomized placebo-controlled trial of Sarilumab in hospitalized patients with Covid-19.","volume":"3","author":"Sivapalasingam","year":"2021","journal-title":"medRxiv"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"691712","DOI":"10.3389\/fmed.2021.691712","article-title":"Methylprednisolone pulses plus tacrolimus in addition to standard of care vs. standard of care alone in patients with severe COVID-19. a randomized controlled trial.","volume":"8","author":"Solanich","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R56-20250504","first-page":"1","article-title":"Lenzilumab efficacy and safety in newly hospitalized COVID-19 subjects: results from the LIVE-AIR phase 3 randomized double-blind placebo-controlled trial.","volume":"3","author":"Temesgen","year":"2021","journal-title":"medRxiv"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13613-020-00792-3","article-title":"Pilot trial of high-dose vitamin C in critically ill COVID-19 patients.","volume":"11","author":"Zhang","year":"2021","journal-title":"Ann Intensive Care"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"566609","DOI":"10.3389\/fmed.2021.566609","article-title":"A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of \u03b1-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19).","volume":"8","author":"Zhong","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/jmv.27512","article-title":"Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: a network meta-analysis of randomized controlled trials.","volume":"94","author":"Cheng","year":"2022","journal-title":"J Med Virol"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"104872","DOI":"10.1016\/j.phrs.2020.104872","article-title":"Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: a systematic review and meta-analysis.","volume":"157","author":"Zhong","year":"2020","journal-title":"Pharmacol Res"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10787-021-00903-x","article-title":"Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection.","volume":"30","author":"Kumar","year":"2022","journal-title":"Inflammopharmacology"},{"key":"R63-20250504","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1164\/rccm.202108-1859OC","article-title":"Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.","volume":"205","author":"Criner","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R64-20250504","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: Vulnerability, immunity and intervention.","volume":"65","author":"Chen","year":"2021","journal-title":"Ageing Res Rev"},{"key":"R65-20250504","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.18632\/aging.103001","article-title":"COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?","volume":"12","author":"Sargiacomo","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"R66-20250504","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"R67-20250504","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fpubh.2020.00418","article-title":"Racial and gender-based differences in COVID-19.","volume":"8","author":"Kopel","year":"2020","journal-title":"Front Public Health"},{"key":"R68-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11481-020-09974-z","article-title":"Is COVID-19 gender-sensitive?","volume":"16","author":"Mukherjee","year":"2021","journal-title":"J Neuroimmune Pharmacol"},{"key":"R69-20250504","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00705-020-04911-0","article-title":"Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations.","volume":"166","author":"Sarkar","year":"2021","journal-title":"Arch Virol"},{"key":"R70-20250504","doi-asserted-by":"crossref","first-page":"108409","DOI":"10.1016\/j.clim.2020.108409","article-title":"Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic.","volume":"215","author":"Gasmi","year":"2020","journal-title":"Clin Immunol"},{"issue":"1S","key":"R71-20250504","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.chest.2020.03.013","article-title":"Randomized controlled trials.","volume":"158","author":"Zabor","year":"2020","journal-title":"Chest"},{"key":"R72-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jmv.26254","article-title":"Microstructure, pathophysiology, and potential therapeutics of COVID-19: a comprehensive review.","volume":"93","author":"Singh","year":"2021","journal-title":"J Med Virol"},{"key":"R73-20250504","first-page":"12593","article-title":"Possible treatment and strategies for COVID-19: review and assessment.","volume":"24","author":"Trivedi","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R74-20250504","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3201\/eid1005.030640","article-title":"Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients.","volume":"10","author":"Wang","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"R75-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/M13-2486","article-title":"Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection.","volume":"160","author":"Arabi","year":"2014","journal-title":"Ann Intern Med"},{"key":"R76-20250504","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14712598.2021.1847269","article-title":"A comprehensive review on sarilumab in COVID-19.","volume":"21","author":"Khiali","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R77-20250504","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00134-015-4095-4","article-title":"Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients\u2019 data from four randomized trials and trial-level meta-analysis of the updated literature.","volume":"42","author":"Meduri","year":"2016","journal-title":"Intensive Care Med"},{"key":"R78-20250504","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China.","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R79-20250504","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jconrel.2020.10.009","article-title":"Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.","volume":"329","author":"Formiga","year":"2021","journal-title":"J Control Release"},{"key":"R80-20250504","doi-asserted-by":"crossref","first-page":"1753466620951053","DOI":"10.1177\/1753466620951053","article-title":"Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.","volume":"14","author":"Yates","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"R81-20250504","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1021\/acsptsci.0c00140","article-title":"Ivermectin, famotidine, and doxycycline: a suggested combinatorial therapeutic for the treatment of COVID-19.","volume":"3","author":"Sen Gupta","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"R82-20250504","doi-asserted-by":"crossref","first-page":"102565","DOI":"10.1016\/j.autrev.2020.102565","article-title":"Imatinib might constitute a treatment option for lung involvement in COVID-19.","volume":"19","author":"Bernal-Bello","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R83-20250504","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2213-2600(22)00052-2","article-title":"Long-term clinical outcomes of COVID-19 patients treated with imatinib.","volume":"10","author":"Duijvelaar","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R84-20250504","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"R85-20250504","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.cmi.2021.05.020","article-title":"An open-label randomized controlled trial of the effect of lopinavir\/ritonavir, lopinavir\/ritonavir plus IFN-\u03b2-1a and hydroxychloroquine in hospitalized patients with COVID-19.","volume":"27","author":"Ader","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R86-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s15010-020-01557-7","article-title":"Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.","volume":"49","author":"Lin","journal-title":"Infection"},{"key":"R87-20250504","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.3390\/jcm9072050","article-title":"Role of Lopinavir\/Ritonavir in the treatment of Covid-19: a review of current evidence, guideline recommendations, and perspectives.","volume":"9","author":"Meini","year":"2020","journal-title":"J Clin Med"},{"key":"R88-20250504","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients.","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"R89-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19.","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat Med"},{"key":"R90-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3947\/ic.2020.0109","article-title":"Effectiveness of mavrilimumab in viral infections including SARS-CoV-2 infection - a brief review.","volume":"53","author":"Bhatt","year":"2021","journal-title":"Infect Chemother"},{"key":"R91-20250504","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","article-title":"Age-specific mortality and immunity patterns of SARS-CoV-2.","volume":"590","author":"O\u2019Driscoll","year":"2021","journal-title":"Nature"},{"key":"R92-20250504","doi-asserted-by":"crossref","first-page":"607408","DOI":"10.3389\/fphar.2021.607408","article-title":"Evaluation of the current therapeutic approaches for COVID-19: a systematic review and a meta-analysis.","volume":"12","author":"Abdelrahman","year":"2021","journal-title":"Front Pharmacol"},{"key":"R93-20250504","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/00498254.2021.1909782","article-title":"Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens.","volume":"51","author":"Karatza","year":"2021","journal-title":"Xenobiotica"},{"key":"R94-20250504","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2019.22525","article-title":"Effect of intravenous interferon \u03b2-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial.","volume":"323","author":"Ranieri","year":"2020","journal-title":"JAMA"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:30:17Z","timestamp":1746336617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":91,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030998","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}